全文获取类型
收费全文 | 23767篇 |
免费 | 1904篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 226篇 |
儿科学 | 998篇 |
妇产科学 | 775篇 |
基础医学 | 3066篇 |
口腔科学 | 241篇 |
临床医学 | 3025篇 |
内科学 | 4147篇 |
皮肤病学 | 665篇 |
神经病学 | 2315篇 |
特种医学 | 502篇 |
外科学 | 2434篇 |
综合类 | 305篇 |
一般理论 | 37篇 |
预防医学 | 3252篇 |
眼科学 | 320篇 |
药学 | 1571篇 |
中国医学 | 22篇 |
肿瘤学 | 1832篇 |
出版年
2023年 | 268篇 |
2022年 | 157篇 |
2021年 | 761篇 |
2020年 | 507篇 |
2019年 | 834篇 |
2018年 | 867篇 |
2017年 | 643篇 |
2016年 | 670篇 |
2015年 | 712篇 |
2014年 | 971篇 |
2013年 | 1387篇 |
2012年 | 2109篇 |
2011年 | 2271篇 |
2010年 | 1171篇 |
2009年 | 1034篇 |
2008年 | 1676篇 |
2007年 | 1770篇 |
2006年 | 1620篇 |
2005年 | 1407篇 |
2004年 | 1221篇 |
2003年 | 1107篇 |
2002年 | 994篇 |
2001年 | 175篇 |
2000年 | 110篇 |
1999年 | 137篇 |
1998年 | 157篇 |
1997年 | 98篇 |
1996年 | 76篇 |
1995年 | 83篇 |
1994年 | 69篇 |
1993年 | 51篇 |
1992年 | 67篇 |
1991年 | 52篇 |
1990年 | 47篇 |
1989年 | 43篇 |
1988年 | 47篇 |
1987年 | 59篇 |
1986年 | 52篇 |
1985年 | 30篇 |
1984年 | 28篇 |
1983年 | 26篇 |
1982年 | 27篇 |
1981年 | 19篇 |
1980年 | 12篇 |
1979年 | 19篇 |
1978年 | 9篇 |
1976年 | 10篇 |
1974年 | 11篇 |
1973年 | 11篇 |
1971年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Bhavana Pothuri Allison L. Brodsky Joseph A. Sparano Stephanie V. Blank Mimi Kim Dawn L. Hershman Amy Tiersten Brian F. Kiesel Jan H. Beumer Leonard Liebes Franco Muggia 《Cancer chemotherapy and pharmacology》2020,85(4):741-751
Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in breast and recurrent gynecologic cancer patients. Veliparib and PLD were administered in a standard phase 1, 3 + 3 dose-escalation design starting at 50 mg veliparib BID on days 1–14 with PLD 40 mg/mg2 on day 1 of a 28-day cycle. Dose escalation proceeded in two strata: A (prior PLD exposure) and B (no prior PLD exposure). Patients underwent limited pharmacokinetic (PK) sampling; an expansion PK cohort was added. 44 patients with recurrent ovarian or triple negative breast cancer were enrolled. Median age 56 years; 23 patients BRCA mutation carriers; median prior regimens four. Patients received a median of four cycles of veliparib/PLD. Grade 3/4 toxicities were observed in 10% of patients. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. Two BRCA mutation carriers had complete responses. Two BRCA patients developed oral squamous cell cancers after completing this regimen. PLD exposure was observed to be higher when veliparib doses were > 200 mg BID. The RP2D is 200 mg veliparib BID on days 1–14 with 40 mg/m2 PLD on day 1 of a 28-day cycle. Anti-tumor activity was seen in both strata. However, given development of long-term squamous cell cancers and the PK interaction observed, efforts should focus on other targeted combinations to improve efficacy. 相似文献
2.
Freda Cooner Margaret Gamalo-Siebers Amy Xia Aijun Gao Shiling Ruan Tony Jiang 《Statistics In Biopharmaceutical Research》2020,12(2):210-223
AbstractChildren are considered a vulnerable group and as such are granted additional protection as research subjects. Research projects using children as research subjects are justifiable if the answer to the scientific question of the study cannot be obtained by enrolling adult subjects (cf. scientific necessity). Thus, there is an ethical obligation to explore innovative analytical strategies that seek balance between the feasibility of conducting a trial and maximizing the utilization of data on efficacy and safety. On this note, there is enthusiasm for implementing some less popular but efficient alternative designs for confirmatory pediatric trials. Within the pediatric extrapolation paradigm, examples of such designs, other than purely based on pharmacokinetic/pharmacodynamic data, are described in this article along with their advantages and disadvantages. This article will also discuss how to incorporate alternative data sources in the analysis of pediatric clinical trials. A discussion of existing approaches and a road-map to their utilization will be provided. Real case examples on the use of the approaches are provided. 相似文献
3.
4.
Emarene Kalaw Malcolm Lim Jamie R. Kutasovic Anna Sokolova Lucinda Taege Kate Johnstone James Bennett Jodi M. Saunus Colleen Niland Kaltin Ferguson Irma Gresshoff Mark Bettington Nirmala Pathmanathan Gary M. Tse David Papadimos Rajadurai Pathmanathan Gavin Harris Rin Yamaguchi Puay Hoon Tan Stephen Fox Sandra A. O’Toole Peter T. Simpson Sunil R. Lakhani Amy E. McCart Reed 《British journal of cancer》2020,123(11):1665
5.
Ashton A. Connor Robert E. Denroche Gun Ho Jang Mathieu Lemire Amy Zhang Michelle Chan-Seng-Yue Gavin Wilson Robert C. Grant Daniele Merico Ilinca Lungu John M.S. Bartlett Dianne Chadwick Sheng-Ben Liang Jenna Eagles Faridah Mbabaali Jessica K. Miller Paul Krzyzanowski Heather Armstrong Steven Gallinger 《Cancer cell》2019,35(2):267-282.e7
6.
7.
Phantana-angkool April Voci Amy E. Warren Yancey E. Livasy Chad A. Beasley Lakesha M. Robinson Myra M. Hadzikadic-Gusic Lejla Sarantou Terry Forster Meghan R. Sarma Deba White Richard L. 《Annals of surgical oncology》2019,26(12):3874-3882
Annals of Surgical Oncology - The role of sentinel lymph node biopsy (SLNB) when ductal carcinoma in situ with microinvasion (DCISM) is identified on core biopsy is unclear. Our aim was to assess... 相似文献
8.
9.
10.
P.V. Chernyshov A. Lallas L. Tomas‐Aragones M. Arenbergerova M. Samimi L. Manolache A. Svensson S.E. Marron F. Sampogna S. Spillekom‐vanKoulil A. Bewley A.M. Forsea G.B. Jemec J.C. Szepietowski M. Augustin A.Y. Finlay 《Journal of the European Academy of Dermatology and Venereology》2019,33(5):816-827
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer (NMSC) present a review of the literature and position statement on health‐related (HR) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology‐specific, cancer‐specific, SC‐specific, facial SC‐specific, NMSC‐specific, basal cell carcinoma‐specific and melanoma‐specific QoL questionnaires have been used to assess HRQoL in SC patients. HRQoL was assessed in the context of creation and validation of the HRQoL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQoL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQoL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ‐C30), the Functional Assessment of Cancer Therapy‐Melanoma (FACT‐M), Skin Cancer Index (SCI), Short Form 36 Item Health Survey (SF‐36) and the Dermatology Life Quality Index (DLQI). The TFs recommend the use of the cancer‐specific EORTC QLQ‐C30, especially in late stages of disease, and the melanoma‐specific FACT‐M and SC‐specific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQoL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology‐specific HRQoL instruments can be used to assess the impact of skin‐related problems in SC. The TFs encourage further studies to validate HRQoL instruments for use in different stages of SC, in order to allow more detailed practical recommendations on HRQoL assessment in SC. 相似文献